Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | CRHBP | P24387 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.66 |
| ▸ | RNF4 | P78317 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | PNLIP | P16233 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9813659 | 0.94 | ALDH1A1 (0.60) | HPGDSMN1; SMN2PGRNPC1CRHBP | |
| SCHEMBL30053559 | 0.88 | CA12 (0.73) | HPGDSMN1; SMN2PGRNPC1CRHBP | |
| SCHEMBL21295380 | 0.86 | CA12 (0.71) | HPGDSMN1; SMN2PGRRAB9ATGM2 | |
| SCHEMBL6353164 | 0.84 | TGM2 (0.67) | HPGDSMN1; SMN2PGRNPC1CRHBP | |
| SCHEMBL8006359 | 0.84 | HPGD (0.66) | HPGDSMN1; SMN2PGRNPC1CRHBP | |
| SCHEMBL11390139 | 0.84 | ALDH1A1 (0.58) | HPGDSMN1; SMN2PGRNPC1RNF4 | |
| SCHEMBL5528916 | 0.84 | SMN1; SMN2 (0.66) | HPGDSMN1; SMN2PGRNPC1CRHBP | |
| SCHEMBL21316586 | 0.84 | HPGD (0.66) | HPGDSMN1; SMN2PGRNPC1CRHBP | |
| SCHEMBL11394952 | 0.84 | NPC1 (0.66) | HPGDSMN1; SMN2PGRNPC1RAB9A | |
| SCHEMBL5149569 | 0.84 | TGM2 (0.56) | HPGDSMN1; SMN2PGRNPC1CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212295-B1 | SUBSTITUTED ALPHA-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2008-10-01 | — | — | EP | claimed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| CN-1729171-A | Modulation of anxiety by blocking hydrolysis of arachidonoylethanolamide | UNIV CALIFORNIA (US) | 2006-02-01 | — | — | CN | claimed |
| CN-1235875-C | Substituted alpha-hydroxy acid caspase inhibitors and uses thereof | CYTOVIA INC (US) | 2006-01-11 | — | — | CN | claimed |
| EP-1317430-B1 | (2-AZABICYCLO [2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GMBH (DE) | 2005-05-18 | — | — | EP | claimed |
| US-20040039045-A1 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | claimed |
| CN-1382119-A | Substituted alpha-hydroxy acid caspase inhibitors and uses thereof | CYTOVIA INC (US) | 2002-11-27 | — | — | CN | claimed |
| EP-3759088-B1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | AlzeCure Pharma AB (SE) | 2022-06-07 | — | — | US | disclosed |
| EP-3759088-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | Alzecure Pharma AB (SE) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2020-12-24 | — | — | US | disclosed |
| WO-2019162702-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2019-08-29 | — | — | WO | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| US-20040039045-A1 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
| WO-2004002401-A2 | CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS | CYTOVIA, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003065989-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
| CN-1382119-A | Substituted alpha-hydroxy acid caspase inhibitors and uses thereof | CYTOVIA INC (US) | 2002-11-27 | — | — | CN | disclosed |
| US-4279637-A | Herbicidal N-substituted 4-imidazolin-2-ones | VELSICOL CHEMICAL CORPORATION (US) | 1981-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039045-A1 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | CHRNA1, CHRNA10, CHRNB1 | HPGD 2224/4885SMN1; SMN2 2350/4885PGR 1734/4885 |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | HPGD 495/4885SMN1; SMN2 1362/4885PGR 4709/4885 |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | NTRK2, BDNF, NGF | HPGD 1087/4885SMN1; SMN2 619/4885PGR 419/4885 |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | HPGD 1087/4885SMN1; SMN2 619/4885PGR 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.